Current Report Filing (8-k)
20 Junio 2023 - 3:31PM
Edgar (US Regulatory)
0001858685
false
0001858685
2023-06-16
2023-06-16
0001858685
BFRI:CommonStockParValue0.001PerShareMember
2023-06-16
2023-06-16
0001858685
BFRI:PreferredStockPurchaseRightsMember
2023-06-16
2023-06-16
0001858685
BFRI:WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember
2023-06-16
2023-06-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): June 16, 2023
Biofrontera
Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40943 |
|
47-3765675 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
120
Presidential Way, Suite 330
Woburn,
Massachusetts |
|
01801 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (781) 245-1325
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange
on
which registered |
Common
stock, par value $0.001 per share |
|
BFRI |
|
The
Nasdaq Stock Market LLC |
Preferred
Stock Purchase Rights |
|
|
|
The
Nasdaq Stock Market LLC |
Warrants,
each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share |
|
BFRIW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the “Exchange Act”) (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
4.01 |
Changes
in Registrant’s Certifying Accountant |
On
June 16, 2023 (the “Engagement Date”), Biofrontera Inc. (the “Company”) engaged Marcum LLP (“New
Auditor”) as its independent registered public accounting firm for the Company’s fiscal year ended December 31, 2023.
The decision to engage the New Auditor as the Company’s independent registered public accounting firm was approved by the
Company’s Audit Committee and Board of Directors. As previously reported, the Company’s prior registered independent
public accountant Grant Thornton LLP resigned on May 30, 2023, as was disclosed in the Company’s Current Report on Form 8-K on
June 2, 2023.
During
the two most recent fiscal years ended December 31, 2022 and 2021 and through the Engagement Date, neither the Company nor anyone on
its behalf has consulted with the New Auditor regarding either:(i) the application of accounting principles to a specific transaction,
either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither
a written report nor oral advice was provided to the Company that the New Auditor concluded was an important factor considered by the
Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject
of a disagreement (as defined in Regulation S-K, Item 304(a) (1)(iv) and the related instructions) or any reportable event (as defined
in Regulation S-K, Item 304(a)(1)(v)).
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
June
20, 2023
(Date) |
Biofrontera
Inc.
(Registrant) |
|
|
|
/s/
E. Fred Leffler III |
|
E.
Fred Leffler III |
|
Chief
Financial Officer |
Biofrontera (NASDAQ:BFRI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Biofrontera (NASDAQ:BFRI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024